Know the compound.
Profiles of GLP-1 drugs, peptides, testosterone and anabolic steroids, approved and not. Each one covers what it is, its regulatory status, how strong the evidence is and the known risks. No doses. Reviewed .
GLP-1 and related drugs
| Compound | Class | FDA status | Grade |
|---|---|---|---|
| Semaglutide Ozempic, Wegovy, Rybelsus | GLP-1 receptor agonist | FDA-approved | A |
| Tirzepatide Mounjaro, Zepbound | GIP and GLP-1 receptor agonist | FDA-approved | A |
| Liraglutide Victoza, Saxenda | GLP-1 receptor agonist | FDA-approved | A |
| Dulaglutide Trulicity | GLP-1 receptor agonist | FDA-approved | A |
| Orforglipron Foundayo | Oral GLP-1 receptor agonist (not a peptide) | FDA-approved | A |
| Retatrutide Reta, LY3437943 | GIP, GLP-1 and glucagon receptor agonist | Investigational, not approved | B |
FDA-approved peptides
| Compound | Class | FDA status | Grade |
|---|---|---|---|
| Tesamorelin Egrifta | Growth-hormone-releasing hormone analog | FDA-approved, narrow use | B |
| Bremelanotide (PT-141) Vyleesi | Melanocortin receptor agonist | FDA-approved, narrow use | B |
| Sermorelin Geref (discontinued) | Growth-hormone-releasing hormone analog | Formerly approved, now compounded | C |
Popular peptides, not approved
| Compound | Class | FDA status | Grade |
|---|---|---|---|
| BPC-157 Body protection compound | Synthetic peptide | Not FDA-approved | D |
| TB-500 Thymosin beta-4 fragment | Synthetic peptide | Not FDA-approved | D |
| CJC-1295 and ipamorelin Often sold as a blend | Growth hormone secretagogues | Not FDA-approved | C |
| MOTS-c Mitochondria-derived peptide | Peptide | Not FDA-approved | D |
| GHK-Cu Copper tripeptide | Copper-binding peptide | Not FDA-approved | D |
| Melanotan II MT-II | Non-selective melanocortin agonist | Not FDA-approved | D |
Testosterone and anabolic steroids
| Compound | Class | FDA status | Grade |
|---|---|---|---|
| Testosterone (TRT) Cypionate, enanthate, undecanoate | Androgen | FDA-approved, Schedule III | A |
| Trenbolone Tren | Anabolic steroid | Not approved for humans, Schedule III | D |
| Nandrolone Deca, nandrolone decanoate | Anabolic steroid | FDA-approved use, Schedule III | B |
| Oxandrolone Anavar, Oxandrin | Oral anabolic steroid | Approval withdrawn 2023, Schedule III | C |
| Oxymetholone Anadrol | Oral anabolic steroid | FDA-approved use, Schedule III | B |
| Stanozolol Winstrol | Anabolic steroid | Discontinued in the US, Schedule III | C |
| Drostanolone Masteron | Anabolic steroid | Not marketed in the US, Schedule III | C |
| Methenolone Primobolan, Primo | Anabolic steroid | Not marketed in the US, Schedule III | C |
| Methandrostenolone Dianabol, Dbol | Oral anabolic steroid | Not marketed in the US, Schedule III | C |
| Boldenone Equipoise, EQ | Veterinary anabolic steroid | Not approved for humans, Schedule III | D |
How the evidence grades work
AApproved, large human trials.
BHuman trials, narrow or pending approval.
CLimited, early or dated human data.
DAnimal and lab data only.
A lower grade does not prove a compound fails. It means nobody has shown that it works or that it is safe. More on grading the evidence.